Table 4 Demographic data of patients with partial response and failure to predominant sodium channel blocking antiseizure medications
|  | All (n = 24) | Partial response (n = 5) | Failure (n = 19) | p |
|---|---|---|---|---|
Onset age | 15.0 (6.0–19.5) | 6.5 (1.3–14.0) | 16.0 (10.0–21.0) | 0.586 |
Male | 10 (41.7) | 2 (40.0) | 8 (42.1) | reference |
Female | 14 (58.3) | 3 (60.0) | 11 (57.9) | 1.000 |
Seizure type | ||||
 Focal | 17 (70.8) | 2 (40.0) | 15 (78.9) | 0.224 |
 Generalized | 5 (20.8) | 2 (40.0) | 3 (15.8) |  |
 Unspecified | 2 (8.3) | 1 (20.0) | 1 (5.3) |  |
Etiology | ||||
 Structural | 5 (20.8) | 1 (20.0) | 4 (21.1) | 0.331 |
 CNS infection | 1 (4.2) | 1 (20.0) | 0 (0.0) |  |
 Genetic | 1 (4.2) | 0 (0.0) | 1 (5.3) |  |
 Autoimmune | 2 (8.3) | 0 (0.0) | 2 (10.5) |  |
 Unknown | 15 (62.5) | 3 (60.0) | 12 (63.2) |  |
Number of ASMs | ||||
 1 | 6 (25.0) | 1 (20.0) | 5 (26.3) | 0.965 |
 2 | 10 (41.7) | 2 (40.0) | 8 (42.1) |  |
 3 | 7 (29.2) | 2 (40.0) | 5 (26.3) |  |
 4 | 0 (0.0) | 0 (0.0) | 0 (0.0) |  |
 5 | 1 (5.9) | 0 (0.0) | 1 (5.3) |  |
Concurrent ASMs | ||||
 Carbamazepine | 8 | 2 | 6 |  |
 Clobazam | 1 | 0 | 1 |  |
 Gabapentin | 1 | 0 | 1 |  |
 Lacosamide | 2 | 1 | 1 |  |
 Lamotrigine | 10 | 1 | 9 |  |
 Levetiracetam | 14 | 3 | 11 |  |
 Oxcarbazepine | 4 | 2 | 2 |  |
 Perampanel | 1 | 0 | 1 |  |
 Phenobarbital | 1 | 0 | 1 |  |
 Phenytoin | 9 | 2 | 7 |  |
 Vigabatrin | 1 | 0 | 1 |  |